Received May 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | UNK | — | — |
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | UNK | — | — |
not symptomatic, no addtional AE; HCP calling to report administrations of VARIVAX and PROQUAD on 05/02/2026 for 13-month-old twin patients. Patients are not symptomatic. Unable to collect LOT/EXP for the VARIVAX and PROQUAD. No other information at this time. Permission to contact g; This spontaneous report was received from a Nurse and refers to a 13-months-old patient of unknown gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 02-May-2025, the patient started therapy with Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD), (Strength, dose, dose number, frequency, vaccination scheme, route, anatomical location, lot #, and expiration date were not reported), as prophylaxis. On the same date, the patient was also vaccinated with Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX), (Strength, dose, dose number, frequency, vaccination scheme, route, anatomical location, lot #, and expiration date were not reported), as prophylaxis (inappropriate schedule of vaccina administered). The patient was not symptomatic, and no additional adverse event reported. This is one of two reports from the same reporter. Lot # is being requested and will be submitted if received.
Sterile diluent